ClearRead CT Lung Tissue Analysis (LTA)
Analysis of hypodense lung tissue (e.g., for emphysema)
Key Facts
About Riverain Technologies
Riverain Technologies is a pioneer and commercial leader in AI-powered chest imaging analysis, founded in 2004. The company's FDA-cleared ClearRead platform addresses critical needs in lung cancer screening (pulmonary nodules), cardiovascular risk assessment (coronary artery calcification scoring), and other thoracic conditions by reducing visual clutter and automating detection tasks. With a strong installed base at over 400 locations globally and a high customer retention rate, Riverain is positioned at the intersection of the rapidly growing AI diagnostics and population health management markets. Its focus on proven clinical utility and workflow integration has established it as a trusted partner for major healthcare providers.
View full company profile